Healthcare Infection Control Practices Advisory Committee (HICPAC), 35546-35547 [2014-14617]
Download as PDF
<![CDATA[
35546
Federal Register / Vol. 79, No. 120 / Monday, June 23, 2014 / Notices
Scholar in Residence in the Health
Sector Management Program at Duke
University’s Fuqua School of Business,
and William J. Hall, MD, Director of the
Center for Healthy Aging at the
University of Rochester School of
Medicine.
In addition, Commissioner Jon B.
Christianson, Ph.D., Professor in the
Division of Health Policy and
Management at the School of Public
Health at the University of Minnesota in
Minneapolis has been designated as
Vice Chair of the Commission. [42
U.S.C. 1395b–6.]
Gene L. Dodaro,
Comptroller General of the United States.
[FR Doc. 2014–14500 Filed 6–20–14; 8:45 am]
BILLING CODE 1610–02–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Melanie Cokonis, Southern Research
Institute: Based on the report of an
investigation conducted by Southern
Research Institute (SRI) and additional
analysis conducted by ORI in its
oversight review, ORI found that Ms.
Melanie Cokonis, former Research
Technician, SRI, engaged in research
misconduct in research supported by
National Institute of Allergy and
Infectious Diseases (NIAID), National
Institutes of Health (NIH), contracts
N01–AI–30047
(HHSN2722011000009C) and N01–AI–
70042 (HHSN272200700042C), and
National Human Genome Research
Institute (NHGRI), NIH, grant U54
HG005034.
ORI found that the Respondent
engaged in research misconduct by
falsifying assay data that were submitted
in reports to NIH. Specifically, ORI
found that Respondent knowingly
falsified data for cytoprotection assays
with antiviral compounds and provided
the false data for inclusion in reports
submitted to NIH for contracts N01–AI–
30047 and N01–AI–70042 and grant
U54 HG005034. Respondent transferred
raw data from 8X12 SoftmaxPro matrix
files into spreadsheets and then falsified
the numbers for cell control, virus
control, drug cytotoxicity, drug only,
and/or cells+ virus+ drug wells to make
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:33 Jun 20, 2014
Jkt 232001
206 assays appear to have been
successfully performed when they were
not.
Ms. Cokonis has voluntarily agreed
for a period of three (3) years, beginning
on May 29, 2014:
(1) To exclude herself from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility or involvement in
nonprocurement programs of the United
States Government referred to as
‘‘covered transactions’’ pursuant to
HHS’ Implementation (2 CFR part 376 et
seq) of OMB Guidelines to Agencies on
Governmentwide Debarment and
Suspension, 2 CFR part 180 (collectively
the ‘‘Debarment Regulations’’); and
(2) To exclude herself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8800.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–14627 Filed 6–20–14; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Committee on Breast Cancer
in Young Women, Centers for Disease
Control and Prevention: Notice of
Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the
Advisory Committee on Breast Cancer
in Young Women, Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS), has been renewed for a
2-year period through June 17, 2016.
For information, contact Temeika L.
Fairley, Ph.D., Designated Federal
Officer, Advisory Committee on Breast
Cancer in Young Women, HHS, CDC,
4770 Buford Highway NE., Mailstop
K52, Atlanta, Georgia 30341, telephone
770/488–4518, fax 770/488–4760.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Prevention and the Agency for Toxic
Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–14616 Filed 6–20–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Healthcare Infection Control Practices
Advisory Committee (HICPAC)
In accordance with section 10(a) (2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) announce
the following meeting for the
aforementioned committee:
Times and Dates:
9:00 a.m.–5:00 p.m., July 17, 2014
9:00 a.m.–12:00 p.m., July 18, 2014
Place: CDC, Global Communications
Center, Building 19, Auditorium B3, 1600
Clifton Road, Atlanta, Georgia, 30333
Status: Open to the public, limited only by
the space available. Please register for the
meeting at www.cdc.gov/hicpac.
Purpose: The Committee is charged with
providing advice and guidance to the
Director, Division of Healthcare Quality
Promotion, the Director, National Center for
Emerging and Zoonotic Infectious Diseases
(NCEZID), the Director, CDC, the Secretary,
Department of Health and Human Services
regarding (1) the practice of healthcare
infection prevention and control; (2)
strategies for surveillance, prevention, and
control of infections, antimicrobial
resistance, and related events in settings
where healthcare is provided; and (3)
periodic updating of CDC guidelines and
other policy statements regarding prevention
of healthcare-associated infections and
healthcare-related conditions.
Matters for Discussion: The agenda will
include updates on the Draft Guideline to
Prevent Surgical Site Infections; the Draft
Guideline to Prevent Infections in Neonatal
Intensive Care Units; CDC’s activities for
prevention of antimicrobial resistant
healthcare associated infections; updates on
prevention and surveillance of catheterassociated urinary tract infections; and
HICPAC core infection prevention and
control practices.
Agenda items are subject to change as
priorities dictate.
Contact Person For More Information: Erin
Stone, M.S., HICPAC, Division of Healthcare
Quality Promotion, NCEZID, CDC, 1600
Clifton Road NE., Mailstop A–07, Atlanta,
Georgia 30333, Telephone: (404) 639–4045,
Email: hicpac@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
E:\FR\FM\23JNN1.SGM
23JNN1
35547
Federal Register / Vol. 79, No. 120 / Monday, June 23, 2014 / Notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office Centers for Disease Control
and Prevention.
[FR Doc. 2014–14617 Filed 6–20–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
Title: Federal Strategic Action Plan on
Services for Victims of Human
Trafficking: Enhancing the Health Care
System’s Response to Human
Trafficking.
OMB No.: New Collection.
Description: In 2013, the U.S.
Department of Health and Human
Services co-chaired an inter-agency
process with the Departments of Justice
and Homeland Security to create the
first Federal Strategic Action Plan on
Services for Victims of Human
Trafficking in the United States. The
Plan addresses the needs for the
implementation of coordinated,
effective, culturally appropriate and
trauma informed care for victims of
human trafficking. The purpose of this
initiative is to develop a pilot training
project that will strengthen the health
systems’ response to human trafficking
in four key ways:
1. Increase knowledge about human
trafficking among health care providers;
2. Build the capacity of health care
providers to deliver culturally
appropriate and trauma-informed care
to victims of human trafficking;
3. Increase the identification of
victims of human trafficking; and
4. Increase services to survivors of
human trafficking.
The evaluation is an impact
evaluation, measuring immediate
outcomes, e.g., from pre-intervention to
post-intervention, as well as
intermediate outcomes at a 3 month
post intervention.
Respondents: The target audience for
training and evaluation will be 300
health care providers from hospitals,
clinics, and private health practices.
The health care providers will be from
federal, state/territorial, and local health
departments, the Veterans’
Administration, professional
associations, and tribal institutions.
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
emcdonald on DSK67QTVN1PROD with NOTICES
Training ............................................................................................................
Pre-training ......................................................................................................
Post-training .....................................................................................................
Email Follow-up ...............................................................................................
Telephone Follow-up .......................................................................................
Telephone Follow-up .......................................................................................
Estimated Total Annual Burden
Hours:
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 370
L’Enfant Promenade SW., Washington,
DC 20447, Attn: ACF Reports Clearance
Officer. All requests should be
identified by the title of the information
collection. Email address:
infocollection@acf.hhs.gov.
OMB Comment:
OMB is required to make a decision
concerning the collection of information
between 30 and 60 days after
publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication. Written comments and
recommendations for the proposed
information collection should be sent
directly to the following: Office of
Management and Budget, Paperwork
Reduction Project, Email: OIRA_
SUBMISSION@OMB.EOP.GOV, Attn:
VerDate Mar<15>2010
17:33 Jun 20, 2014
Jkt 232001
300
300
300
60
60
60
Desk Officer for the Administration for
Children and Families.
Robert Sargis,
Reports Clearance Officer.
[FR Doc. 2014–14577 Filed 6–20–14; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Comment Request
Title: Health Profession Opportunity
Grants (HPOG) program.
OMB No.: 0970–0394.
Description: The Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services (HHS) is proposing data
collection activities as part of the Health
Profession Opportunity Grants (HPOG)
program. The proposed data collection
activities described in this notice will
provide data for the Impact Studies of
the Health Profession Opportunity
Grants (HPOG-Impact) and the National
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1
1
1
1
1
1
Average
burden hours
per response
2.0
.40
.40
.40
.40
.40
Total burden
hours
600.00
120.00
120.00
120.00
24.00
984.00
Implementation Evaluation of the
Health Profession Opportunity Grants to
Serve TANF Recipients and Other LowIncome Individuals (HPOG–NIE).
The goal of HPOG-Impact is to
evaluate the effectiveness of approaches
used by 20 of the HPOG grantees to
provide TANF recipients and other lowincome individuals with opportunities
for education, training and advancement
within the health care field. HPOGImpact also is intended to evaluate
variation in participant impact that may
be attributable to different HPOG
program components and models. The
impact study design is a classic
experiment in which eligible applicants
will be randomly assigned to a
treatment group that is offered
participation in HPOG and a control
group that is not permitted to enroll in
HPOG. In a subset of sites, eligible
applicants will be randomized into two
treatment arms (a basic and an
enhanced version of the intervention)
and a control group.
The goal of HPOG–NIE is to describe
and assess the implementation, systems
change, and outcomes and other
important information about the
operations of the 27 HPOG grantees
E:\FR\FM\23JNN1.SGM
23JNN1
]]>Agencies
[Federal Register Volume 79, Number 120 (Monday, June 23, 2014)]
[Notices]
[Pages 35546-35547]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-14617]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Healthcare Infection Control Practices Advisory Committee
(HICPAC)
In accordance with section 10(a) (2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announce the following meeting for the aforementioned
committee:
Times and Dates:
9:00 a.m.-5:00 p.m., July 17, 2014
9:00 a.m.-12:00 p.m., July 18, 2014
Place: CDC, Global Communications Center, Building 19,
Auditorium B3, 1600 Clifton Road, Atlanta, Georgia, 30333
Status: Open to the public, limited only by the space available.
Please register for the meeting at www.cdc.gov/hicpac.
Purpose: The Committee is charged with providing advice and
guidance to the Director, Division of Healthcare Quality Promotion,
the Director, National Center for Emerging and Zoonotic Infectious
Diseases (NCEZID), the Director, CDC, the Secretary, Department of
Health and Human Services regarding (1) the practice of healthcare
infection prevention and control; (2) strategies for surveillance,
prevention, and control of infections, antimicrobial resistance, and
related events in settings where healthcare is provided; and (3)
periodic updating of CDC guidelines and other policy statements
regarding prevention of healthcare-associated infections and
healthcare-related conditions.
Matters for Discussion: The agenda will include updates on the
Draft Guideline to Prevent Surgical Site Infections; the Draft
Guideline to Prevent Infections in Neonatal Intensive Care Units;
CDC's activities for prevention of antimicrobial resistant
healthcare associated infections; updates on prevention and
surveillance of catheter-associated urinary tract infections; and
HICPAC core infection prevention and control practices.
Agenda items are subject to change as priorities dictate.
Contact Person For More Information: Erin Stone, M.S., HICPAC,
Division of Healthcare Quality Promotion, NCEZID, CDC, 1600 Clifton
Road NE., Mailstop A-07, Atlanta, Georgia 30333, Telephone: (404)
639-4045, Email: hicpac@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices
[[Page 35547]]
pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and Services Office Centers for
Disease Control and Prevention.
[FR Doc. 2014-14617 Filed 6-20-14; 8:45 am]
BILLING CODE 4163-18-P
